このエントリーをはてなブックマークに追加
ID 52029
FullText URL
Author
Wada, Tadashi
Nakahama, Makoto
Toda, Hironobu
Watanabe, Atsuyuki
Hashimoto, Katsushi
Terasaka, Ritsuko
Nakamura, Kazufumi Kaken ID researchmap
Yamada, Nobuyuki
Ito, Hiroshi Kaken ID
Abstract
Dual antiplatelet therapy (DAPT) after percutaneous coronary intervention increases the risk of bleeding. We studied the safety and clinical outcomes of switching from DAPT to aspirin monotherapy at 3 months after ZES implantation. We retrospectively evaluated 168 consecutive patients with coronary artery disease who had been implanted with a ZES from June 2009 through March 2010. After excluding 40 patients according to exclusion criteria such as myocardial infarction, 128 patients were divided into a 3-month DAPT group (67 patients, 88 lesions) and a 12-month conventional DAPT group (61 patients, 81 lesions). Coronary angiographic followup and clinical followup were conducted at more than 8 months and at 12 months after ZES implantation, respectively. Minor and major bleeding events, stent thrombosis (ST), and major adverse cardiac events (MACE) (death, myocardial infarction, cerebrovascular accident, target lesion revascularization, and target vessel revascularization) were evaluated. There were no statistically significant differences in the incidences of ST and MACE between the two groups. The incidence of bleeding events was significantly lower in the 3-month group than in the 12-month group (1.5% versus 11.5%, ). DAPT can be safely discontinued at 3 months after ZES implantation, which reduces bleeding risk.
Published Date
2013
Publication Title
ISRN Cardiology
Volume
volume2013
Publisher
Hindawi Publishing Corporation
Content Type
Journal Article
Official Url
http://dx.doi.org/10.1155/2013/518968
Related Url
http://ousar.lib.okayama-u.ac.jp/metadata/51960
language
英語
Copyright Holders
© 2013 Tadashi Wada et al.
File Version
publisher
Refereed
True
DOI